Condition: Schizophrenia · Sponsor: University Hospital, Tours
Schizophrenia affects about 0.7% of the population. Poor insight, which is common in this disease, linked to poor drug compliance is leads to rehospitalisation with major impact on quality of life. Indeed, many patients relapse with exacerbation of symptoms. Psychoeducation can improve therapeutic alliance and medication compliance. In this context, an individual psycho-education program (PEPITS) has been developed. PEPITS carried out by nurses during the initial stages of hospitalisation. The hypothesis is that PEPITS program will decrease relapse and improve the compliance and insight and and so the quality of life.
This description comes directly from the study's public registry record.
Arnaud CHESSE · +33(0)2.34.37.89.68 · A.CHESSE@chu-tours.fr
Marie LECLERC · +33(0)2.47.47.46.64 · m.leclerc@chu-tours.fr
Always discuss trial participation with your own doctor first.
| Serrvice de Psychiatrie | Blois, France | Withdrawn |
| Service de psychiatrie | Chinon, France | Recruiting |
| Service de psychiatrie | Dreux, France | Not Yet Recruiting |
| Service de psychiatrie | Fleury-les-Aubrais, France | Withdrawn |
| Service de psychiatrie | La Roche-sur-Yon, France | Recruiting |
| Service de psychiatrie | Neuilly-sur-Marne, France | Not Yet Recruiting |
| Service de psychiatrie | Rennes, France | Recruiting |
| Service de psychiatrie | Saint-Maurice, France | Not Yet Recruiting |
| Service de psychiatrie | Sainte-Gemmes-sur-Loire, France | Recruiting |
| Service de psychiatrie | Sotteville-lès-Rouen, France | Not Yet Recruiting |
| Service de psychiatrie | Tours, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05329363